These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 32327162)

  • 1. Cost-Effectiveness of Intranasal Naloxone Distribution to High-Risk Prescription Opioid Users.
    Acharya M; Chopra D; Hayes CJ; Teeter B; Martin BC
    Value Health; 2020 Apr; 23(4):451-460. PubMed ID: 32327162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Take-Home Naloxone for the Prevention of Overdose Fatalities among Heroin Users in the United Kingdom.
    Langham S; Wright A; Kenworthy J; Grieve R; Dunlop WCN
    Value Health; 2018 Apr; 21(4):407-415. PubMed ID: 29680097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal in Russian cities.
    Coffin PO; Sullivan SD
    J Med Econ; 2013 Aug; 16(8):1051-60. PubMed ID: 23730942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal.
    Coffin PO; Sullivan SD
    Ann Intern Med; 2013 Jan; 158(1):1-9. PubMed ID: 23277895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An economic evaluation of community pharmacy-dispensed naloxone in Canada.
    Cid A; Mahajan N; Wong WWL; Beazely M; Grindrod KA
    Can Pharm J (Ott); 2024; 157(2):84-94. PubMed ID: 38463179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care.
    Schackman BR; Leff JA; Polsky D; Moore BA; Fiellin DA
    J Gen Intern Med; 2012 Jun; 27(6):669-76. PubMed ID: 22215271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioid education and nasal naloxone rescue kits in the emergency department.
    Dwyer K; Walley AY; Langlois BK; Mitchell PM; Nelson KP; Cromwell J; Bernstein E
    West J Emerg Med; 2015 May; 16(3):381-4. PubMed ID: 25987910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of alternative naloxone distribution strategies: First responder and lay distribution in the United States.
    Townsend T; Blostein F; Doan T; Madson-Olson S; Galecki P; Hutton DW
    Int J Drug Policy; 2020 Jan; 75():102536. PubMed ID: 31439388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings.
    Bailey AM; Wermeling DP
    Ann Pharmacother; 2014 May; 48(5):601-6. PubMed ID: 24523396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing pharmacists' readiness to dispense naloxone and counsel on responding to opioid overdoses.
    Melaragni F; Levy C; Pedrazzi J; Andersen M
    J Am Pharm Assoc (2003); 2019; 59(4):550-554.e2. PubMed ID: 31109812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementing take-home naloxone in an urban community pharmacy.
    Akers JL; Hansen RN; Oftebro RD
    J Am Pharm Assoc (2003); 2017; 57(2S):S161-S167. PubMed ID: 28202384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of naloxone distribution alone or in combination with addiction treatment with or without pre-exposure prophylaxis for HIV prevention in people who inject drugs: a cost-effectiveness modelling study.
    Uyei J; Fiellin DA; Buchelli M; Rodriguez-Santana R; Braithwaite RS
    Lancet Public Health; 2017 Mar; 2(3):e133-e140. PubMed ID: 29253386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reducing overdose deaths among persons with opioid use disorder in connecticut.
    Scheidell JD; Townsend TN; Zhou Q; Manandhar-Sasaki P; Rodriguez-Santana R; Jenkins M; Buchelli M; Charles DL; Frechette JM; Su JI; Braithwaite RS
    Harm Reduct J; 2024 May; 21(1):103. PubMed ID: 38807226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rates and Costs of Dispensing Naloxone to Patients at High Risk for Opioid Overdose in the United States, 2014-2018.
    Barenie RE; Gagne JJ; Kesselheim AS; Pawar A; Tong A; Luo J; Bateman BT
    Drug Saf; 2020 Jul; 43(7):669-675. PubMed ID: 32180134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementation of a naloxone dispensing program in a grocery store-based community pharmacy.
    Wilkerson DM; Groves BK; Mehta BH
    Am J Health Syst Pharm; 2020 Mar; 77(7):511-514. PubMed ID: 32086505
    [No Abstract]   [Full Text] [Related]  

  • 16. An increase in per-patient naloxone requirements in an opioid epidemic.
    Birmingham LE; Nielson JA
    Am J Emerg Med; 2017 Dec; 35(12):1958-1959. PubMed ID: 28633907
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness of naloxone kits in secondary schools.
    Cipriano LE; Zaric GS
    Drug Alcohol Depend; 2018 Nov; 192():352-361. PubMed ID: 30321745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonprescription naloxone and syringe sales in the midst of opioid overdose and hepatitis C virus epidemics: Massachusetts, 2015.
    Stopka TJ; Donahue A; Hutcheson M; Green TC
    J Am Pharm Assoc (2003); 2017; 57(2S):S34-S44. PubMed ID: 28189540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of full and partial opioid agonists for opioid use disorder in outpatient settings: United States healthcare sector perspective.
    Choi SA; Yan CH; Gastala NM; Touchette DR; Stranges PM
    J Subst Use Addict Treat; 2024 May; 160():209237. PubMed ID: 38061629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is known about community pharmacy supply of naloxone? A scoping review.
    Nielsen S; Van Hout MC
    Int J Drug Policy; 2016 Jun; 32():24-33. PubMed ID: 26949189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.